Chitosan-coated PLGA Nanoparticles |
Determine whether PLGA
nanoparticles improve the therapeutic efficacy of curcumin through
stimulation of its antioxidant and anti-inflammatory properties |
Not
Specified |
2 mg/kg |
In vitro and in vivo with SH-SY5Y
and BV-2 cells |
The synthesized nanoparticle decreased the
anti-inflammatory biomarkers, IL-6 and TNF-a, by 40% and 70%
respectively. Additionally, curcumin biocompatibility, penetration, and
bioaccumulation were greater when chitosan-coated PLGA nanoparticles
were administered. |
101,102 |
Hydroxypropyl-β-cyclodextrin-encapsulated curcumin nanoparticles |
Develop a nanoparticulate system for enhanced delivery and penetration
of curcumin in brain tissue |
Not Specified |
2 mg/kg |
In vitro
and in vivo with SH-SY5Y and BV-2 cells |
The
hydroxypropyl-β-cyclodextrin encapsulated curcumin nanoparticles had
enhanced biostability when compared to curcumin-loaded chitosan-coated
PLGA nanoparticles. Furthermore, these nanoparticles had significantly
higher bioaccumulation in brain cells than curcumin-loaded
chitosan-coated PLGA nanoparticles and free curcumin. The synthesized
nanoparticles also had comparable anti-inflammatory effects to
curcumin-loaded chitosan-coated PLGA nanoparticles. |
101,102 |
PLGA nanoparticles functionalized with red blood cell (RBC) membranes
and tau-PET tracers |
Synthesize a nanoparticulate system that
demonstrates enhanced permeation through the BBB to effectively target
hyperphosphorylated tau proteins |
Not Mentioned |
Not Mentioned |
In vitro and in vivo with transgenic mouse models |
The
PLGA nanoparticles functionalized with RBC membranes and tau-PET tracers
demonstrated enhanced efficacy in penetrating the BBB and showed a
significant affinity for hyperphosphorylated tau. Further in
vitro and in vivo studies showed that the synthesized NPs
decreased phosphorylated tau levels, neuronal cell death, and memory
deficits. |
103 |
PLGA nanoparticles loaded with amyloid-β generation inhibitor (S1) &
curcumin, and conjugated with transferrin receptor targeting CRT peptide |
Implement a nanoparticle delivery system that is capable of overcoming
the following limitations posed by free drug delivery for treatment of
AD: ineffective BBB penetration, limited bioavailability, and low
circulation times |
128.6-139.8 nm |
0.5 mg/kg and 2 mg/kg |
In
vitro and in vivo studies with SH-SY5Y human neuroblastoma
cells, BV2 mouse microglial cells, and bEnd.3 mouse-derived brain
capillary endothelial cells. |
Y-maze and object recognition tests
showed that the synthesized NPs significantly improved spatial memory in
AD transgenic mice. Furthermore, these NPs reduced amyloid-β levels,
reactive oxygen species (ROS), and anti-inflammatory biomarkers (i.e.,
TNF-α and IL-6). Along with these benefits, the S1 and curcumin loaded
PLGA NPs functionalized with CRT restored optimal superoxide dismutase
activities and facilitated synaptogenesis in AD mouse brains. |
104 |
PEGylated dendrigraft poly-L-lysine nanoparticles
|
Develop an interventional nanoparticulate system to downregulate BACE 1,
an essential enzyme implicated in the formation of amyloid-β plaques and
tau-related fibrils
|
Not Specified
|
50 µg
|
In vitro: brain capillary endothelial cells and SH-SY5Y cells
In vivo: APPswe and PSEN1dEP transgenic mice
|
Successful delivery of the antisense siRNA BACE and tau-related fibril
inhibitor peptide was achieved. Furthermore, the PEGylated dendrigraft
poly-L-lysine nanoparticles significantly decreased positive BACE 1
signals and phosphorylated-tau levels in AD mouse models.
|
105
|